Previous 10 | Next 10 |
Aytu and Innovus Shareholder Meetings to Approve Merger Scheduled for February 13, 2020 ENGLEWOOD, CO & SAN DIEGO, CA / ACCESSWIRE / January 27, 2020 / Aytu BioScience, Inc. (NASDAQ:AYTU), a specialty pharmaceutical company focused on commercializing novel products that address sign...
Aytu BioScience (NASDAQ: AYTU ) and Innovus Pharmaceuticals ( OTCQB:INNV ) have filed Form S-4 containing a joint preliminary proxy statement/prospectus in connection with Aytu's proposed acquisition of Innovus on December 23, 2019 after markets closed. More news on: Aytu BioScience, Inc...
ENGLEWOOD, CO and SAN DIEGO, CA / ACCESSWIRE / December 24, 2019 / Aytu BioScience, Inc. (NASDAQ:AYTU), a specialty pharmaceutical company focused on commercializing novel products that address significant patient needs and Innovus Pharmaceuticals, Inc. (OTCQB:INNV), a specialty pharmaceutic...
The following slide deck was published by Aytu BioScience, Inc. in conjunction with this Read more ...
ENGLEWOOD, CO / ACCESSWIRE / December 5, 2019 / Aytu BioScience, Inc. (NASDAQ:AYTU), a specialty pharmaceutical company focused on commercializing novel products that address significant patient needs, announced that MiOXSYS ® will be featured in a Product Symposium at the 8 th Annual...
ENGLEWOOD, CO / ACCESSWIRE / December 3, 2019 / Aytu BioScience, Inc. (NASDAQ:AYTU), a specialty pharmaceutical company focused on global commercialization of novel products addressing significant medical needs, today announced that Josh Disbrow, Chairman and Chief Executive Officer, and Dav...
Aytu BioScience (NASDAQ: AYTU ) in co-promotion with Acerus Pharmaceuticals has launched a U.S.-based specialty sales force promoting Natesto to urologists and endocrinologists. More news on: Aytu BioScience, Inc., Healthcare stocks news, Read more ...
Acerus Launches U.S. Specialty Sales Force; Sales Team Expansion Nearly Doubles Current Natesto Sales Force Expanded Commercial Operations Expected to Accelerate Natesto Growth in the U.S. ENGLEWOOD, CO / ACCESSWIRE / December 2, 2019 / Aytu BioScience, Inc. (NASDAQ:AYTU), a speci...
Provides More Than Six Million US Lives Unrestricted Access to Only FDA-Approved 12-Hour Codeine-Based Cold-Cough Syrup ENGLEWOOD, CO / ACCESSWIRE / November 19, 2019 / Aytu BioScience, Inc. (NASDAQ:AYTU), a specialty pharmaceutical company focused on global commercialization of novel p...
Aytu BioScience, Inc. (AYTU) Q1 2020 Earnings Conference Call November 14, 2019, 16:30 ET Company Participants Joshua Disbrow - Chairman & CEO David Green - CFO, Secretary & Treasurer Conference Call Participants Jeffrey Cohen - Ladenburg Thalmann & Co. Carl Byr...
News, Short Squeeze, Breakout and More Instantly...
Company receives proceeds of $3.5 million through exercise of warrants, a portion of which was used to pay down debt Interest rate on new $13.0 million term loan reduced by approximately 350 basis points today, potentially saving the Company $1.3 million over the life of the term loan T...
Phoenix, Arizona and New York, New York--(Newsfile Corp. - May 29, 2024) - Lytham Partners, a leading investor relations and corporate access firm, today announced the schedule for its Spring 2024 Investor Conference taking place virtually on May 30, 2024. More than 40 companies will be available...
DENVER, CO / ACCESSWIRE / May 23, 2024 / Aytu BioPharma, Inc. (the Company or "Aytu") (NASDAQ:AYTU), a pharmaceutical company focused on commercializing novel therapeutics, today announced that Josh Disbrow, CEO, will participate in a webcasted fireside chat and host one-on-one meetings with inv...